Cardio-Oncology-Beyond Anthracyclines and Ejection Fraction
- PMID: 38823894
- DOI: 10.1016/j.hlc.2024.05.002
Cardio-Oncology-Beyond Anthracyclines and Ejection Fraction
Keywords: Cardio-Oncology; Cardiology; Cardiovascular disease; Cardiovascular toxicity; Oncology; Risk management.
Conflict of interest statement
Disclosures ALS is supported by the National Heart Foundation of Australia Future Leader Fellowship (award ID 106025). ALS has received research grants from Novartis, RACE Oncology and Bristol Myers Squibb; and speaker fees from Novartis, AstraZeneca and Janssen. There are no other relevant author disclosures.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
